Back to results
US 9,957,573 B2Granted
EML4-ALK translocations in lung cancer
AssigneeQuest Diagnostics Investments Incorporated
InventorsHeather R. Sanders, Maher Albitar, Aurelia Meloni-Ehrig
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.
Claims9
A kit for detecting a EML4-ALK fusion mutation in a nucleic acid sample comprising at least one oligonucleotide comprising the sequence of SEQ ID NOs:
- 27 or 28, or complements thereof, wherein the at least one oligonucleotide is labeled with a reporter dye.
Dependencies are inferred from the claim text.